This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Bayer, Monsanto EU review takes expected course as objections land

By Dafydd Nelson ( December 15, 2017, 15:14 GMT | Comment) -- The EU's charge sheet against Bayer's planned acquisition of Monsanto has sunk the German company's dream of completing the acquisition by the end of the year. But such a step is par for the course, and Bayer still has a reasonable chance of completing the deal in the coming quarter.Bayer's attempts to close its purchase of Monsanto by year-end, and to avoid formal EU charges against the $66 billion takeover, have failed. But that’s not necessarily a problem for the German pharmaceuticals company....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login